Recurrent brain abscesses in an HIV-positive patient with hereditary hemorrhagic telangiectasia and arteriovenous malformations of the lung

Patients with hereditary hemorrhagic telangiectasia are at risk for the development of brain abscesses. The history of a 47-year-old man infected with the human immunodeficiency virus and with hereditary hemorrhagic telangiectasia is reported. Within eight months, the patient presented twice with li...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical microbiology & infectious diseases 1996-05, Vol.15 (5), p.407-410
Main Authors: THURNHEER, R, VERNAZZA, P. L, GALEAZZI, R. L
Format: Article
Language:English
Subjects:
AIDS/HIV
Anti-Bacterial Agents - therapeutic use
Arteriovenous Fistula - complications
Biological and medical sciences
Brain Abscess - complications
Brain Abscess - physiopathology
Brain Abscess - therapy
Drainage
HIV Infections - complications
HIV Infections - physiopathology
Homosexuality, Male
human immunodeficiency virus
Humans
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
Male
Medical sciences
Middle Aged
Recurrence
Streptococcal Infections - complications
Streptococcal Infections - therapy
Telangiectasia, Hereditary Hemorrhagic - complications
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with hereditary hemorrhagic telangiectasia are at risk for the development of brain abscesses. The history of a 47-year-old man infected with the human immunodeficiency virus and with hereditary hemorrhagic telangiectasia is reported. Within eight months, the patient presented twice with life-threatening cerebral abscesses at different sites. On both occasions, Streptococcus anginosus was cultured from the abscess material. Treatment consisted of parenteral antibiotics and neurosurgical drainage. After treatment of the second occurrence, the patient was placed on a prophylactic regimen of clindamycin. He remains relapse-free and is clinically stable 24 months after the second episode.
ISSN:0934-9723
1435-4373
DOI:10.1007/BF01690100